HDT Bio is a clinical stage private company developing advanced RNA vaccine products to treat and prevent infectious diseases and cancers. Leveraging its proprietary LION™ technology with superior safety, potency, durability, and manufacturing advantages.
HDT Bio is a clinical stage private company developing advanced RNA vaccine products to treat and prevent infectious diseases and cancers. Leveraging its proprietary LION™ technology with superior safety, potency, durability, and manufacturing advantages.
HDT Bio is a clinical stage private company developing advanced RNA vaccine products to treat and prevent infectious diseases and cancers. Leveraging its proprietary LION™ technology with superior safety, potency, durability, and manufacturing advantages.
HDT Bio’s self-replicating RNA (repRNA) vaccines harness the immune system to combat difficult-to-treat conditions and improve patient lives worldwide.
The AMPLIFY vaccine platform — The next generation of RNA vaccines
HDT’s RNA vaccine platform combines its self-amplifying RNA (“repRNA”) and LION™ technology to provide increased potency compared to traditional mRNA vaccines.
Latest News
Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
Click here to view article
Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines
Click here to view article
HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative
HDT bio's Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ -- HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud...